Category: Examples

ASH Abstract+Video Collection Demo

Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Overall Survival in Alcyone Abstract Presentation View author list and disclosures Author(s): Maria-Victoria Mateos, Michele Cavo, Joan Bladé, MD PhD, Meletios A. Dimopoulos, MD, Kenshi Suzuki, MD PhD, Andrzej Jakubowiak, MD PhD, Stefan Knop, Chantal Doyen,…

Read the full article

ASH Video + Abstract 2

Abstract #143 – First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial Abstract Presentation View Authors and Disclosures Author(s) Luciano J. Costa, MD PhD, Sandy W. Wong, Arancha Bermúdez, Javier de la Rubia,…

Read the full article

ASH Video + Abstract

Abstract #143 – First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial Abstract Presentation View Authors and Disclosures Author(s) Luciano J. Costa, MD PhD, Sandy W. Wong, Arancha Bermúdez, Javier de la Rubia,…

Read the full article

ePrint Collection

For demonstration purposes only. Not for general distribution. Efficacia e sicurezza a lungo termine del trattamento di prima linea con ibrutinib per i pazienti con CLL/SLL: 5 anni di follow-up dallo studio RESONATE-2 di fase 3 Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase…

Read the full article